secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0000875045-24-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q1 EPS up 8% non-GAAP; LEQEMBI sales triple Q4 to $19M; reaffirms FY guide
--------------------------------------------------------------------------------

- Q1 total revenue $2.3B (-7% YoY); GAAP diluted EPS $2.70 (+1%); Non-GAAP diluted EPS $3.67 (+8%).
- LEQEMBI global in-market sales ~$19M, nearly triple Q4 2023; patients on therapy up ~2.5x since end 2023.
- SKYCLARYS Q1 global revenue $78M; U.S. launch progressing, E.U. launch underway.
- Full-year 2024 guidance reaffirmed: Non-GAAP EPS $15-16 (mid-point ~5% growth); operating margin improvement expected.
- SPINRAZA U.S. revenue +1%, outside U.S. impacted by competition and shipment timing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000012/0000875045-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000012/biib-20240424.htm
  HTML page:      https://secwatch.observer/filing/0000875045-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer